##
##
##
||||Page|
|---|---|---|---|
|Administrative|and statutory
details|||
|Message I'rom the National Director|||2-8|
|Report ofthe|Trustees||9 - 14|
|Independent|Auditors'|report|15- 18|
|Accounts comprising:||||
|Statement of|financial|activities|19|
|Statement of|financial|position|20|
|Statement of|cashflows||21|
|Notes to the financial||statements|22-32|
##
|||ADMINISTRATIVE
AND STATUTORY DETAILS|ADMINISTRATIVE
AND STATUTORY DETAILS|ADMINISTRATIVE
AND STATUTORY DETAILS|
|---|---|---|---|---|
|Board ofTrustees||Mark Silverman|||
|||Gary Fegan|||
|||Roger Cockerton|(Treasurer)||
|||Victoria Penrice|||
|National Director||Florence Boulton|||
|Scientific|Advisory Board|Dame Professor K||Davies —Chair|
|||Professor M Wood||—Vice Chair|
|Registered|oAice|Wellesley House|||
|||Duke ofWellington||Avenue|
|||Royal Arsenal|||
|||London|||
|||SE]86SS|||
|Auditors||Simpson Wreford|LLP||
|||Wellesley House|||
|||Duke ofWellington||Avenue|
|||Royal Arsenal|||
|||London|||
|||SE186SS|||
|Company|number|04899036|||
|Charity number||1101971|||
|||SC043852 (Scotland)|||
|Solicitors||Morgan Cole|||
|||Bradley Court|||
|||Park Place|||
|||Cardiff|||
|||CF103DR|||
|Banks||Barclays Bank|||
|||PO Box3|||
|||77North Street,|||
|||Keighley|||
|||BD213SA|||
|||The Co-operative|Bank Pic||
|||POBox250|||
|||Skelmersdale|||
|||N3 6WT|||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||2023|2023|2023|2022|
|---|---|---|---|---|---|---|
||||Unresticted|Restricted|Total|Total|
|||Notes|funds|funds|funds|funds|
|Income and endowments|from:|4|||||
|Donations
and legacies|||]64,669|128,814|293,483|347,160|
|Charitable
activities||||257,442|257,442|98,960|
|Other trading activities|||160,911||160,911|114,797|
|Investments|||28||28|19|
|Other - Government
grants||||||I 250|
|Total income|||~325608|3~86256|7~11864|~562 186|
|Expenditure
on:||16|||||
|Raising funds:|||||||
|Cost ofevents and general|fundraising||35,725||35,725|75,320|
|Charitable
activities:|||||||
|Campaigning
and education,|||40,528|87,680|128,208|79,040|
|Research, supporting
families,|||||||
|and grants payable|||153,057|227,596|380,653|173,887|
|Improved
management
and|||||||
|medical care|||36259||36259|31616|
|Total expenditure|||~265569|315276|~580845|~359863|
|Net income/(expenditure)|||60,039|70,980|131,019|202,323|
|Transfers between
funds|||||||
|Net movement
in funds|||~60039|~70980|~131019|202 323|
|Reconciliation offunds:|||||||
|Balance at 1 April 2022|||420 156|240|420 396|218073|
|Balance at 31March 2023|||||||
##
##
||Notes|Notes|2023||2022|
|---|---|---|---|---|---|
|Fixed assets||||||
|Tangible assets|||2,161||2,881|
|Investments|||2||2|
||||2,163||2,883|
|Current
assets||||||
|Debtors||7|6,948|11,049||
|Cash at bank|and in hand|20|625039|475 928||
||||631,987|486,977||
|Current liabilities||||||
|Creditors
due within one year|||(~82 735|35 222||
|Net current|assets||549252||451 755|
|Total assets|less current liabilities||551,415||454,638|
|Creditors due more than one year||9|||34.242|
|Net assets||15|~551415||~420396|
|Represented|by:|||||
|Resnicted funds||13|71,220||240|
|Unrestricted|funds|14|480 195||420 156|
||||||~420396|
##
|||||2023|2022|
|---|---|---|---|---|---|
||||Notes|Total|Total|
|Cashfloivs from operating|activities:|||||
|Net cash provided by operating
activities|||19|194066|88 454|
|Cashflows from investing|activities:|||||
|Dividends,
interest, and rents from investments||||28|19|
|Purchase ofequipment|||||(2,772)|
|Proceeds from disposal oftangibles||||||
|Net cash (used in) by investing
activites||||28|~2753)|
|Cashflows from financing|activities:|||||
|Loan received||||||
|Interest paid||||(719)|(2,034)|
|Net cash (used in)/provided|by financing|activites||~44 264|~4486|
|Change in cash and cash equivalents
in the reporting period||||149,111|79,181|
|Cash and cash equivalents|as at 1 April 2022||20|475 928|396747|
|Cash and cash equivalents|as at 3 l March|2023|20|~2||
##
##
##
##
##
##
##
|Costs to the|company were as follows:|||
|---|---|---|---|
|||2023|2022|
|Gross wages:||||
|- projects||242,636|187,551|
|- non-projects||26,615|18,169|
|Staffpension||5,847|7,013|
|Employer's|Nl contributions|19901|14826|
|||~294 999|227 559|
|||||||2023|2022|
|---|---|---|---|---|---|---|---|
|||||||Number|Number|
||Management|-FTE||||1.0|1.0|
||Research - FTE|||||1.0|1.0|
||Supporting|families - FTE||||5.5|4.0|
||Fundraising|- FTE||||1.2|1.2|
||Advocacy/Campaigns||-|FTE||0.3|0.8|
|3.|Net incoming
resources|||is stated after charging||||
|||||||2023|2022|
||||||||K|
||Auditors'
fees|||||7,800|6,500|
||Independent|examination||and accountancy|fees|12,646|8,253|
||Depreciation|||||720||
##
##
|||||Unresticted|Restricted|2023|2022|
|---|---|---|---|---|---|---|---|
|||||funds|funds|Total|Total|
||Donations
and|legacies||||||
||-Grants ofageneral||nature||128,814|128,814|139,968|
||-Membership
subscriptions|||10,012||10,012|41,217|
||-Fundraising
income|||142,160||142,160|145,966|
||-Gift Aid|||12,497||12,496|13,831|
||-Other||||||6,178|
||Charitable
activities|||||||
||-Performance
related||grants||257,442|257,442|98,960|
||- Other|||||||
||Other trading|activities||||||
||-Fuudraising
events|||||||
||-Non-charitable|trading activities||160,911||160,911|114,594|
||-Shop income||||||203|
||Investments|||28||28|19|
||Other —Government||grants||||I 250|
|||||325608|~386256|~711864||
|5.|Tangible assets|||||||
|||||Computer|Fixtures|Office||
|||||equipment|dc fittings|equipment|Total|
||Cost|||||||
||At I April 2022|||2,772||1,425|4,197|
||Additions|||||||
||Disposals|||||||
||31March 2023|||2.772||I 425|4 197|
||Depreciation|||||||
||At I Apdl 2022|||693||623|1,316|
||Charge fpr the year|||520||200|720|
||Disposals|||||||
||At 31March 2023|||1213||823|2036|
||Net book value|||||||
||At 31March 2023|||||||
||At 31 March 2022|||||||
##
|6.|Investments|||||
|---|---|---|---|---|---|
|||||2023|2022|
||Programme|related investments||||
||Convertible|loan note in Halo Therapeutics|LLC|225,000|225,000|
||Less: trcatcd|as grant paid 2012||~224 999|(~224 999|
|||||I|I|
|2023|2022|
|---|---|
|f.||
|Other|investments|||
|---|---|---|---|
|1,371|Ordinary
shares|of|60.001|
##
##
|Debtors||||||
|---|---|---|---|---|---|
||||2023||2022f|
|Trade debtors|||4,385||3,500|
|Other debtors|||506||3,364|
|Prepayments|||2 057||4 185|
||||6948||11 4|
|Creditors: amounts|falling due within|one year||||
||||2023||2022|
||||||f|
|Trade creditors|||1,062||210|
|Accruals and deferred|income||78,158||22,060|
|Bank loan|||||10,022|
|Other creditors|||3515||2930|
||||~82
35|~1||
##
##
##
|Cred|itors:|am|ounts
faUing due after more than|one year||
|---|---|---|---|---|---|
|||||2023|2022|
||||||f|
|Bank|loans|and|overdrails||34242|
##
##
##
##
##
##
##
##
##
##
|||Unrestricted|Restricted|2023|2022|
|---|---|---|---|---|---|
|||funds|funds|Total|Total|
|Fixed assets||2,163||2,163|2,883|
|Current assets||543,802|88,185|631,987|486,977|
|Current liabilides||(65,770)|(16,965)|(82,735)|(35,222)|
|Non-current|liabilities||||~34242|
##
##
|||||||2023|2022|
|---|---|---|---|---|---|---|---|
|Support costs:||||||||
|Bank charges and interest||||||4,226|4,847|
|Insurance||||||1,364|1,020|
|Wages and salaries||||||294,999|227,559|
|Printing, postage and|stationery|||||6,282|7,251|
|Training, recruitment|and||other|staff costs||35,523|23,687|
|Rent and rates|||||||240|
|Computer
costs||||||19,550|12,029|
|Storage||||||2,561|2,501|
|Telephone
and internet||costs||||4,472|2,559|
|Depreciation
Loss on disposal oftangibles||||||720|960
851|
|Trustees'
meetings|||||||3|
|Governance
costs||||||20,446|14,753|
|Professional
fees||||||17,600|13,834|
|Miscellaneous
expenditure||||||7.102|4 065|
||||||||31
1|
|Support and governance|||costs are allocated as follows:|||||
||||||Support and|Direct||
||||||governance|costs|Total|
|Research, supporting|families,|||and||||
|grants payable 56%|||||234,761|145,891|380,653|
|Fundraising
and events||6.75%|||28,002|7,723|35,725|
|Scientific education 28%|||||116,903|11,305|]28,208|
|improved
management||and medical care 8%|||35 179|1989|36259|
||||||414848|168999|580
45|
##
##
|were|treated as grants payable
during the year:|||
|---|---|---|---|
|||2023|2022|
|Grant|—The University ofNewcastle||21,426|
|Grant|—Queen Mary University
London||25,320|
|Grant|—World Duchenne
Organisation|||
|accounts:|||||||||
|---|---|---|---|---|---|---|---|---|
||||||||2023|2022|
||||||||E||
|Grant to The|University ofGlasgow||||||10590||
||||||||590||
|18.Reconciliation ofnet income||||/ (expenditure)|||to net cashflow from operating
activities||
||||||||2023|2022|
||||||||Total|Total|
|Net surplus/(deficit)|||for the reporting||period||131,019|202,323|
|Adjustments|for:||||||||
|Depreciation|charges||||||720|960|
|Loss on disposal oftangibles||||||||851|
|Interest payable|||||||719|2,034|
|Grant income|related||to bounce|back loan||||(1,250)|
|Dividends,
interest,||and rents from investments|||||(28)|(19)|
|Increase / (decrease)|||in debtors||||4,101|18,612|
|Increase
/ (decrease)|||in creditors||||57535|(~135057|
|Net cash provided||by (used in) operating||||activites||88454|
|19.Analysis of|cash and cash equivalents||||||||
||||||||2023|2022|
||||||||K||
|Cash in hand|||||||625 039|475 928|
||||||||~50|~4|
||||||||31||
##
##
##
|Loans and overdrafts|||
|---|---|---|
||2023|2022|
|Bank loans||~4264|
|Payable within one year||10,022|
|Payable after one year||~4242|
##